MedTrace Logo

Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis

NCT00552461 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-09-28

No results posted yet for this study

Summary

The purpose of this study is to determine whether the use of rituximab is effective in treating pulmonary alveolar proteinosis by leading to an improvement in lung function and disease status.

Conditions

  • Pulmonary Alveolar Proteinosis
  • Primary Disease

Interventions

DRUG

rituximab

IV, 1000 mg, two weeks, 2 times

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • East Carolina University

    lead OTHER

Principal Investigators

  • Mani S Kavuru, MD · East Carolina University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-07-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00552461 on ClinicalTrials.gov